Generating specific homologous neutralizing-antibodies: a novel therapeutic strategy in cancer treatment

Abstract

AbstractCurrent cancer therapeutic strategies still face great challenges especially due to tumor relapse, drug resistance, and low treatment efficiency. The reason is that some tumor cells are able to outsmart the host immune mechanisms and evade the immune system. In this study, using the mouse cutaneous squamous cell carcinoma (mCSCC) as an example, a new cancer immunotherapeutic strategy with homologous neutralizing-antibodies was established. The experiment is divided into three stages. In the first stage, mCSCC cells were isolated and cultured from DMBA/TPA-induced mCSCC. In the second stage, the expanded tumor cells were then injected into healthy mice in order to produce anti-tumor homologous neutralizing-antibodies. In the final stage, therapeutic serum was extracted from healthy mice and injected back into tumor mice. ELISA assay was used to analyze the levels of p53, Bcl-xL, NF-κB, and Bax. The findings demonstrated that the serum treatment reduced tumor volume while also reversing changes in p53, Bcl-xL, NF-κB, and Bax. In conclusion, a novel immunotherapeutic strategy was developed to treat mCSCC, although more study is required to fully understand the mechanism of this serum treatment.